Cargando...
Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose
BACKGROUND: In the era of molecularly targeted agents (MTAs), it is recommended to account for toxicity over several cycles to identify the recommended phase II dose (RP2D). We investigated the relationship between the risk of toxicity at cycle 1 and the cumulative incidence of toxicity over subsequ...
Guardado en:
| Publicado en: | J Natl Cancer Inst |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6855968/ https://ncbi.nlm.nih.gov/pubmed/30838405 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djz024 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|